{"id":"W2946829725","doi":"10.1158/1078-0432.ccr-18-3212","title":"Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK; Astex Pharmaceuticals","keywords":"Abiraterone acetate; Prostate cancer; Pharmacodynamics; Abiraterone; Medicine; Cancer; Prostate; Oncology; Internal medicine; Pharmacology; Pharmacokinetics; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007136328,0.001125272,0.001285189,0.0003118252,0.0002744068,0.0006906172,0.0005767703,0.0005207624,0.002462869],"category_scores_gemma":[0.0006016541,0.0003668591,0.0007327606,0.0003606222,0.0005377746,0.0003826093,0.0001951044,0.002097586,0.0003847217],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006513893,"about_ca_system_score_gemma":0.0009116612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001003538,"about_ca_topic_score_gemma":0.002266591,"domain_scores_codex":[0.9996676,0.0001553605,0.00001785818,0.00004546862,0.0000494566,0.00006425902],"domain_scores_gemma":[0.9994494,0.00008837512,0.0001312821,0.00004334837,0.00004289777,0.0002446745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4215345,0.1038062,0.01190391,0.001183499,0.002354899,0.0004606145,0.0003335825,0.007391814,0.271817,0.0002170055,0.004760263,0.1742367],"study_design_scores_gemma":[0.1541883,0.7661262,0.04704867,0.00005750108,0.001359276,0.0007770698,0.00009860827,0.002422262,0.02321386,0.0001872306,0.004464842,0.00005630804],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960617,0.001740494,0.0003037192,0.0001217776,0.00002726576,0.0003663361,0.0004296437,0.00003187401,0.0009170887],"genre_scores_gemma":[0.9959615,0.001158427,0.0003727249,0.000194724,0.00005613331,0.0002572519,0.001164658,0.00001500268,0.0008195895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002462869,"threshold_uncertainty_score":0.00823909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1538357423929069,"score_gpt":0.5354631624239391,"score_spread":0.3816274200310322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}